Anacor

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

Retrieved on: 
Monday, June 27, 2022
Technology, Other Technology, Health Technology, Stem Cells, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Patient, Biotechnology, Technology, Senior, Therapy, Engineering, BCEL, Bionics, Development, Abhi, Syntex, Boston, Physics, Corporate development, SVP, Hoffmann-La Roche, MIT, Bose Corporation, Doctor of Philosophy, Neuromodulation, Celera Corporation, Quest Diagnostics, NASDAQ, Biomedical engineering, Amgen, Twitter, Paulette, Global, Pfizer, Management, Pharmaceutical industry, Anacor, Medtronic, Electronics, Exelixis, Research, Cellino

Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer.

Key Points: 
  • Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer.
  • We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to Cellino, said Nabiha Saklayen, Ph.D., Chief Executive Officer & Co-Founder, Cellino.
  • Abhi brings over 25 years of experience working on innovative solutions spanning the disciplines of neuroscience, engineering, and physics.
  • Prior to joining Cellino, she was Senior Vice President of Corporate Development and Co-Founder of Atreca, Inc., (NASDAQ: BCEL) a public biopharmaceutical antibody-based company.

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, October 26, 2021
KOL, Eli Lilly and Company, Teaching hospital, Atopic dermatitis, MD, ASLN, Research, MAD, Ferda Mravenec, Icahn School of Medicine at Mount Sinai, University, Master of Science, Anacor, Disease, CA, Eczema Area and Severity Index, Skin, Patient, EASI, DHODH, Secondary research, Intention, ADSS, Company, Crisaborole, University of California, CEO, ADS, AD, Inflammatory bowel disease, Coronavirus Scientific Advisory Board (Turkey), Nasdaq, GLOBE, Mount Sinai, SAB, Bachelor of Medical Sciences, Doctor of Philosophy, Associate, Department, ITT, Pharmaceutical industry, Medical device, Lithium

MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.

Key Points: 
  • MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.
  • Research and development expenses were US$5.3 million in the third quarter of 2021 compared to US$2.2 million in the third quarter of 2020.
  • General and administrative expenses were US$2.8 million in the third quarter of 2021 compared to US$1.3 million in the third quarter of 2020.
  • Net loss for the third quarter of 2021 was US$8.6 million compared to a net loss of US$3.5 million for the third quarter of 2020.

Arcutis Announces Appointment of Keith Leonard to Board of Directors

Retrieved on: 
Thursday, September 2, 2021
Intuitive Surgical, Patient, Unity Biotechnology, Senior, Acquisition, Psoriasis, Risk, UCLA Anderson School of Management, Twitter, Head, Form 10-K, Engineering, Anderson School, Master of Business Administration, U.S. Securities and Exchange Commission, Amgen, Mechanical, Dermatitis, Standard of care, University of California, Solution, General manager, Business administration, University of California, Berkeley, The arts, Biotechnology, Anacor, Nasdaq, SEC, Board, Atopic dermatitis, Physician, Inflammation, Safety, Allergan, University of Maryland, College Park, Information management, Leadership, LinkedIn, University, Marketing, CEO, College Park, GLOBE, NDA, Therapy, Dermatology, Management, Pharmaceutical industry

We thank Ricky for his leadership over the past three years, commented Patrick Heron , Chairman of the Arcutis Board of Directors.

Key Points: 
  • We thank Ricky for his leadership over the past three years, commented Patrick Heron , Chairman of the Arcutis Board of Directors.
  • We are delighted to welcome Keith to the Arcutis Board, said Frank Watanabe , Arcutis President and Chief Executive Officer.
  • Keith adds to the depth of our board with over 25 years of commercial, operational, and international leadership experience.
  • I am thrilled to join the Arcutis board at this pivotal time, said Keith Leonard.

Trevi Therapeutics Announces Additions to the Senior Leadership Team

Retrieved on: 
Monday, August 9, 2021
Movement disorders, San Jose State University, Levodopa-induced dyskinesia, Idiopathic pulmonary fibrosis, Acquisition, Growth, Risk, CAO, Marketing, Safety, PN, U.S. Securities and Exchange Commission, TCOE, Medical Affairs Bureau, Private Securities Litigation Reform Act, Hoffmann-La Roche, Fast Track, COVID-19, Anacor, CPA, Parkinson's disease, Business, Golden Gate University, Deloitte, LID, Lehigh University, Medicis Pharmaceutical, Chronic cough, PRISM, Route of administration, CFO, Therapy, Prurigo nodularis, Knowledge, Itch, Certified Public Accountant, Patient, IPF, Connecticut, General Electric, FDA, Marcum, Publication, Nasdaq, Clinical trial, Nalbuphine, DEA, Communication, Cough, Pharmaceutical industry

New CFO and Vice President, Medical Affairs will be instrumental in Trevi's growth as lead trials move towards data

Key Points: 
  • New CFO and Vice President, Medical Affairs will be instrumental in Trevi's growth as lead trials move towards data
    "We are thrilled to welcome Lisa and Danine to our skilled senior leadership team," said Jennifer L. Good, President and Chief Executive Officer of Trevi.
  • Ms. Delfini joins Trevi with 30 years of experience in the financial sector.
  • As a Financial Accounting and Advisory Services Partner at Marcum LLP, Ms. Delfini led a team of professionals who provided advisory services on financial activities to companies.
  • Before joining Trevi, she held varying senior management roles in medical affairs and marketing at companies such as Anacor Pharmaceuticals, Menlo Therapeutics, Medicis Pharmaceutical, Connetics Corporation, VICOM/FCB and Roche Pharmaceuticals.

Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

Retrieved on: 
Thursday, April 2, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, RTT, Organ systems, Medical specialties, Psoriasis, Immunology, Atopic dermatitis, Anacor, Eczema Area and Severity Index, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant

Im excited to announce the completion of enrollment for our PSOARING Phase 3 clinical trials of tapinarof for the treatment of adult plaque psoriasis, one of the largest topical programs ever undertaken in this indication, said Todd Zavodnick, Chief Executive Officer of Dermavant.

Key Points: 
  • Im excited to announce the completion of enrollment for our PSOARING Phase 3 clinical trials of tapinarof for the treatment of adult plaque psoriasis, one of the largest topical programs ever undertaken in this indication, said Todd Zavodnick, Chief Executive Officer of Dermavant.
  • Dermavant also plans to initiate Phase 3 clinical studies of tapinarof in atopic dermatitis.
  • Tapinarof previously demonstrated clinically meaningful and statistically significant responses in separate Phase 2b trials for plaque psoriasis and atopic dermatitis.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 and PSOARING 2, plus a long-term safety study.

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Retrieved on: 
Monday, March 16, 2020
Autoimmune diseases, RTT, Organ systems, Phosphodiesterase-4 inhibitor, Medical specialties, Steroids, Psoriasis, Dermatitis, Pregnanes, Desonide, Anacor

As no cure for psoriasis exists, patients and dermatologists need new and better topical treatment options to manage this chronic inflammatory condition.

Key Points: 
  • As no cure for psoriasis exists, patients and dermatologists need new and better topical treatment options to manage this chronic inflammatory condition.
  • Based on its safety, tolerability and efficacy profile in our completed clinical trials, we believe topical roflumilast has the potential to be both the best-in-class topical PDE4 inhibitor and the only topical PDE4 inhibitor approved for plaque psoriasis, including in children."
  • Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing Phase 3 clinical trials (Studies ARQ-151-301 and ARQ-151-302) to support registration with the FDA.
  • Arcutis is currently developing three novel compounds (topical roflumilast cream, topical roflumilast foam and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema.

Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis

Retrieved on: 
Monday, July 1, 2019
Children, Biotechnology, Other Health, Pharmaceutical, Consumer, Health, General Health, RTT, Chemistry, Type I hypersensitivity, Medical specialties, Immunology, Crisaborole, Ethers, Atopic dermatitis, Dermatitis, Atopy, Anti-inflammatory, Anacor, the CrisADe CARE 1 Study, Atopic Dermatitis, Crisaborole

Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.
  • These results add to the growing body of evidence that underscores the strength of data for crisaborole as a steroid-free, topical treatment option for people with mild to moderate atopic dermatitis.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis.

2019 Market Spotlight: Atopic Dermatitis - ResearchAndMarkets.com

Retrieved on: 
Friday, June 28, 2019
Health, Other Health, RTT, Medical specialties, Immunology, Companies, Astellas Pharma, Mitsubishi UFJ Financial Group, Dermatitis, Atopic dermatitis, Monoclonal antibodies, Anacor, Fezakinumab

The approved drugs in the atopic dermatitis space focus on a variety of targets.

Key Points: 
  • The approved drugs in the atopic dermatitis space focus on a variety of targets.
  • The majority of industry-sponsored drugs in active clinical development for atopic dermatitis are in Phase II.
  • Mid- and late-stage pipeline drugs in development for atopic dermatitis focus on a wide variety of targets.
  • Novartis leads the industry sponsors with by far the highest number of clinical trials for atopic dermatitis, followed by Pfizer and Astellas.

RAPT Therapeutics Completes $37 Million Series C Extension

Retrieved on: 
Tuesday, June 18, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, Life sciences, Articles, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, Anacor

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical companydeveloping oral small molecules for oncology and inflammatory diseases, today announced that it secured an additional $37 million in an extension of its Series C financing.

Key Points: 
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical companydeveloping oral small molecules for oncology and inflammatory diseases, today announced that it secured an additional $37 million in an extension of its Series C financing.
  • We continue to advance our pipeline of oral small molecule therapeutics, with proof-of-concept results expected in the first half of 2020 from our FLX475 program targeting multiple cancers and in mid-2020 from our RPT193 program in atopic dermatitis, said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics.
  • RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.